Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Feb;139(2):e20162128.
doi: 10.1542/peds.2016-2128. Epub 2017 Jan 3.

A Targeted Approach for Congenital Cytomegalovirus Screening Within Newborn Hearing Screening

Karen B Fowler  1 , Faye P McCollister  2 , Diane L Sabo  3 , Angela G Shoup  4 , Kris E Owen  4 , Julie L Woodruff  5 , Edith Cox  6 , Lisa S Mohamed  6 , Daniel I Choo  7 , Suresh B Boppana  8 ; CHIMES Study
Affiliations

A Targeted Approach for Congenital Cytomegalovirus Screening Within Newborn Hearing Screening

Karen B Fowler et al. Pediatrics. 2017 Feb.

Abstract

Background and objective: Congenital cytomegalovirus (cCMV) infection remains a leading cause of childhood hearing loss. Currently universal CMV screening at birth does not exist in the United States. An alternative approach could be testing infants who do not pass their newborn hearing screening (NHS) for cCMV. This study was undertaken to evaluate whether a targeted approach will identify infants with CMV-related sensorineural hearing loss (SNHL).

Methods: Infants born at 7 US medical centers received NHS and were also screened for cCMV while in the newborn nursery. Infants who tested positive for CMV received further diagnostic audiologic evaluations to identify or confirm hearing loss.

Results: Between 2007 and 2012, 99 945 newborns were screened for both hearing impairment and cCMV. Overall, 7.0% of CMV-positive infants did not pass NHS compared with 0.9% of CMV-negative infants (P < .0001). Among the cCMV infants who failed NHS, diagnostic testing confirmed that 65% had SNHL. In addition, 3.6% of CMV-infected infants who passed their NHS had SNHL confirmed by further evaluation during early infancy. NHS in this cohort identified 57% of all CMV-related SNHL that occurred in the neonatal period.

Conclusions: A targeted CMV approach that tests newborns who fail their NHS identified the majority of infants with CMV-related SNHL at birth. However, 43% of the infants with CMV-related SNHL in the neonatal period and cCMV infants who are at risk for late onset SNHL were not identified by NHS.

PubMed Disclaimer

Conflict of interest statement

POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.

Figures

FIGURE 1
FIGURE 1
Study cohort for the CHIMES study.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Fowler KB, Stagno S, Pass RF. Maternal age and congenital cytomegalovirus infection: screening of two diverse newborn populations, 1980-1990. J Infect Dis. 1993;168(3):552–556 - PubMed
    1. Dollard SC, Grosse SD, Ross DS. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol. 2007;17(5):355–363 - PubMed
    1. Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol. 2007;17(4):253–276 - PubMed
    1. Britt WJ. Cytomegalovirus. In: Remington J, Klein J, Wilson C, Nizet V, Maldonado Y, eds. Infectious Diseases of the Fetus and Newborn Infant. 7th ed. Philadelphia, PA: Elsevier Saunders; 2011:706–755
    1. Dar L, Pati SK, Patro AR, et al. . Congenital cytomegalovirus infection in a highly seropositive semi-urban population in India. Pediatr Infect Dis J. 2008;27(9):841–843 - PubMed